Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

ACCG-2671

First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671

Aconcagua Bio, Inc · Phase 1/2 · Recruiting · Enrollment 164

NCT07815678

ArmPopulationDoseWeeksEstimandWeight change
Part 1 (SAD)Obesity or overweightn/rn/rn/rn/r
Placebo Part 1 (SAD)Obesity or overweightn/rn/rn/rn/r
Part 2 (Food-effect)Obesity or overweightn/rn/rn/rn/r
ACCG-2671 Part 3 (MAD)Obesity or overweightn/rn/rn/rn/r
Placebo Part 3 (MAD)Obesity or overweightn/rn/rn/rn/r